Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tectonic Therapeutic (TECX) Shares Outstanding (Diluted Average) (2021 - 2026)

Tectonic Therapeutic (TECX) has 6 years of Shares Outstanding (Diluted Average) data on record, last reported at $18.8 million in Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 9.39% to $18.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $18.8 million, a 9.39% increase, with the full-year FY2025 number at $18.3 million, up 115.81% from a year prior.
  • Shares Outstanding (Diluted Average) reached $18.8 million in Q1 2026 per TECX's latest filing, up from $18.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for TECX hit a ceiling of $44.0 million in Q1 2023 and a floor of $43695.0 in Q1 2022.
  • A 5-year average of $17.0 million and a median of $17.2 million in 2025 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 102689.93% in 2022, then plummeted 97.23% in 2023.
  • Tracing TECX's Shares Outstanding (Diluted Average) over 5 years: stood at $43.7 million in 2022, then crashed by 97.1% to $1.3 million in 2023, then skyrocketed by 569.3% to $8.5 million in 2024, then soared by 115.81% to $18.3 million in 2025, then grew by 2.44% to $18.8 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TECX at $18.8 million in Q1 2026, $18.3 million in Q4 2025, and $18.2 million in Q3 2025.